These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 14013151)

  • 1. [Hemochromatosis: clinical contribution and new chelating therapy].
    ANGELINO PF; VACCA G
    Minerva Med; 1963 Jun; 54():1849-54. PubMed ID: 14013151
    [No Abstract]   [Full Text] [Related]  

  • 2. [The treatment of hemochromatosis with the new iron chelating agent (desferrioxamine)].
    CONTE M; BODIN F; DUHAMEL
    Bull Mem Soc Med Hop Paris; 1963 Apr 19-26; 114():533-8. PubMed ID: 14022705
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hemochromatosis and iron chelating therapy].
    Hershko C; Link AG; Pinson A; Grisaru S; Sarel S; Grady RW
    Harefuah; 1986 Nov; 111(10):336-8. PubMed ID: 3546013
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of hemochromatosis by chelating agents; three cases].
    LANGERON L; PAGET M; CROCCEL L; ROUTIER G
    Presse Med (1893); 1958 Jul; 66(54):1248-50. PubMed ID: 13567578
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of hemochromatosis].
    WOEHLER F
    Med Klin; 1962 Aug; 57():1370-6. PubMed ID: 14007830
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic & diagnostic import of siderinuria due to chelating agents in hemochromatosis].
    GIRARD M; CREYSSEL R; PANSU C; BEL A; GOLHEN A
    J Med Lyon; 1958 Jan; 39(913):87-94. PubMed ID: 13514366
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of hemochromatosis].
    Crosby WH
    Clin Ter; 1967 Oct; 43(1):3-9. PubMed ID: 5605579
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chelating agents of the edathamil calcium type during ionic overload (iron & lead)].
    LAMACHE A; BOUREL M; CORMIER M; AZARD C; LENOIR P
    Therapie; 1958; 13(2):282-95. PubMed ID: 13556709
    [No Abstract]   [Full Text] [Related]  

  • 9. [Blood transfusion and monitoring. Post-transfusion hemochromatosis].
    Bastion Y
    Soins; 1996 Apr; (605):27-8. PubMed ID: 8716246
    [No Abstract]   [Full Text] [Related]  

  • 10. Neonatal hemochromatosis: it's OK to say "NO" to antioxidant-chelator therapy.
    Leonis MA; Balistreri WF
    Liver Transpl; 2005 Nov; 11(11):1323-5. PubMed ID: 16237698
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chelating agents in the therapy of hemochromatosis. Comments on a case after one year of treatment].
    ALTAVA V; GOMEZ E
    Med Esp; 1960 Aug; 44():122-4. PubMed ID: 13682709
    [No Abstract]   [Full Text] [Related]  

  • 12. Type 3 hemochromatosis and beta-thalassemia trait.
    Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
    Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemochromatosis: Pumping too much iron.
    Regan EN
    Nurse Pract; 2009 Jun; 34(6):25-9. PubMed ID: 19474628
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chelating agents in the treatment of hemochromatosis: comments on a case].
    ALTAVA V; GOMEZ E; PERIS A
    Med Esp; 1959 May; 41(242):401-4. PubMed ID: 13673754
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of hemochromatosis by chelating agents; report of three cases].
    LANGERON L; PAGET M; CROCCEL L; ROUTIER C
    Ann Biol Clin (Paris); 1958; 16(7-9):524-32. PubMed ID: 13595274
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chelating agents in hemochromatosis; therapeutic method or diagnostic test].
    WATER J; WEILL JP
    Presse Med (1893); 1957 Aug; 65(60):1371-3. PubMed ID: 13477735
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of hemochromatosis and its complications].
    Brissot P; Bardou-Jacquet E; Ropert M; Loréal O
    Soins; 2007 Jun; (716):40-2. PubMed ID: 17718032
    [No Abstract]   [Full Text] [Related]  

  • 18. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA; Gama S; Gil M; Gano L
    Hemoglobin; 2008; 32(1-2):147-56. PubMed ID: 18274992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible cardiomyopathy in a patient with juvenile hemochromatosis.
    Blank R; Wolber T; Maeder M; Rickli H
    Int J Cardiol; 2006 Jul; 111(1):161-2. PubMed ID: 15992946
    [No Abstract]   [Full Text] [Related]  

  • 20. Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within human macrophages.
    Olakanmi O; Schlesinger LS; Britigan BE
    J Leukoc Biol; 2007 Jan; 81(1):195-204. PubMed ID: 17038583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.